Lars G. Hemkens (@lghemkens) 's Twitter Profile
Lars G. Hemkens

@lghemkens

Evidence Based Health Care // Pragmatic Evidence || Senior Scientist @RC2NB @Unibasel || RT/like no endorsement

ID: 745640305496625157

linkhttp://www.pragmatic-evidence.org calendar_today22-06-2016 15:31:17

3,3K Tweet

1,1K Takipçi

275 Takip Edilen

Lars G. Hemkens (@lghemkens) 's Twitter Profile Photo

"We estimated 20% probability of detecting new treatments with OR > 50 …Increasing the number of RCTs from about 20 to 40 or 60 per year would double or triple the likelihood of detecting breakthrough treatments with dramatic effects.“

Lars G. Hemkens (@lghemkens) 's Twitter Profile Photo

Wow. Only 1/5 of trials published in the last 10 years in major journals report patient involvement. Need to do much more here! bmj.com/content/389/bm…

Lars G. Hemkens (@lghemkens) 's Twitter Profile Photo

Just 24 participants to go: Our Swisswide pragmatic #MultiSCRIPT trial is close to reaching 915 in about a year. Only possible through full embedding in routine care and with an outstanding team RC2NB and #SMC and the wonderful support of our patients. multiscript.rc2nb.ch

Gordon H. Guyatt (@guyattgh) 's Twitter Profile Photo

Breakthrough for #EBM! #GRADE, leading resource for certainty of evidence and evidence to recommendations now too complex, disorganized. Solution in 7 papers on GRADE essentials “Core GRADE” in #BMJ. This week, introduction to series summarizes content. bmj.com/content/389/bm…

Lars G. Hemkens (@lghemkens) 's Twitter Profile Photo

You can write clinical trial protocols meeting all formal requirements for regulators and ethic committees that produce zero scientific value. Thats a problem. Clinical study protocols are not primarily regulatory documents.

The BMJ (@bmj_latest) 's Twitter Profile Photo

The GRADE approach is the dominant system of rating certainty of evidence and grading healthcare recommendations worldwide. This article introduces a series of papers on new guidance for the GRADE approach bmj.com/content/389/bm…

Marion Campbell (@marionkcampbell) 's Twitter Profile Photo

A major update to the CONSORT reporting guidance for clinical trials was published last week. 📌 CONSORT 2025 replaces all previous versions and should be used from now on. So what’s new and what’s different? 1/7 #MethodologyMonday #116 (COI - I am a co-author)

Gordon H. Guyatt (@guyattgh) 's Twitter Profile Photo

#GRADE, indeed #EBM, will never be the same. GRADE papers have become too complex and difficult to navigate. The remedy: a series of 7 papers in the #BMJ laying out the essentials of GRADE: Core GRADE. This week, an overview of Core GRADE. bmj.com/content/389/bm…

The BMJ (@bmj_latest) 's Twitter Profile Photo

This article is the first in a series describing the fundamental points that authors of systematic reviews, health technology assessment reports, and clinical practice guidelines need to use the Core GRADE approach bmj.com/content/389/bm…

This article is the first in a series describing the fundamental points that authors of systematic reviews, health technology assessment reports, and clinical practice guidelines need to use the Core GRADE approach 
bmj.com/content/389/bm…
Dr. Martin Makary (@drmakaryfda) 's Twitter Profile Photo

I’m proud to welcome Dr. Vinay Prasad, MD, MPH, as the new head of FDA’s Center for Biologics Evaluation & Research. With 500+ peer-reviewed publications and two books, Dr. Prasad brings the kind of scientific rigor, independence, and transparency we need at CBER—a significant

Gordon H. Guyatt (@guyattgh) 's Twitter Profile Photo

Today in #BMJ, 6th in 7 part series on the essentials of #GRADE – Core GRADE: creating excellent Summary of Findings tables allowing clinicians and guideline developers to easily and comprehensively grasp evidence that will assist patients to make optimal decisions.

MSJ (@msj_research) 's Twitter Profile Photo

Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in #MultipleSclerosis. A modified Delphi Study from Lars G. Hemkens Jens Kuhle University of Basel RC2NB ▶️ journals.sagepub.com/doi/full/10.11…

Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in #MultipleSclerosis.

A modified Delphi Study from <a href="/LGHemkens/">Lars G. Hemkens</a> <a href="/JensKuhle/">Jens Kuhle</a> <a href="/UniBasel_en/">University of Basel</a> <a href="/RC2NB/">RC2NB</a> ▶️ journals.sagepub.com/doi/full/10.11…
JAMA (@jama_current) 's Twitter Profile Photo

A single-page digital recruitment letter increased clinical trial enrollment compared to longer letter formats, with no impact from color schemes. ja.ma/40ga7Wo

A single-page digital recruitment letter increased clinical trial enrollment compared to longer letter formats, with no impact from color schemes. 

ja.ma/40ga7Wo
Lars G. Hemkens (@lghemkens) 's Twitter Profile Photo

Excellent meta-research: A trial within a large trial shows that consent form length impacts recruitment. Please consider too much text can exclude vulnerable groups / We need to rethink consent forms, too much information may harm. jamanetwork.com/journals/jama/…

Tor Biering-Sørensen, MD, MSc, MPH, PhD (@torbiering) 's Twitter Profile Photo

Thanks Lars G. Hemkens for the positive feedback on our recently published ‘RCT within a large RCT’. We need to randomize to understand how we can improve processes in our society. The link to our ‘RCT within a RCT’ can be found 👇 jamanetwork.com/journals/jama/… CTCPR Trials & CIRL Niklas Dyrby Johansen

Elmir Omerovic (@elmir1omerovic) 's Twitter Profile Photo

Win Ratio: A Seductive But Potentially Misleading Method for Evaluating Evidence from Clinical Trials | Circulation ahajournals.org/doi/10.1161/CI… This thought-provoking paper critiques the win ratio in a convincingly articulated manner. I'm curious whether the Bayesian approach with

Lars G. Hemkens (@lghemkens) 's Twitter Profile Photo

Wonderful quote: “…one of the problems …is that we may think that our customers are grant review panels or maybe…editors,” …“Those may be our short-term customers, but …not … ultimate customers. Our ultimate customers are people who have to make decisions about healthcare”